| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 2 | +1,471,000 | 49.3% | $18.99 | +$27,936,688 |
| Sells | 10 | -1,510,505 | 50.7% | $13.04 | -$19,694,113 |
| Net | -8 | -39,505 | -1.3% | +$8,242,574 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| GSK plc | 10%+ Owner | $346,668,129 | +$27,930,000 | +8.8% | 11 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. | Director, 10%+ Owner | $121,732,622 | +$6,688 | +0.01% | 13 Nov 2025 |
| KEN TAKANASHI | Director | $44,113,323 | -$42,630 | -0.1% | 11 Aug 2025 |
| Gregory L. Verdine | Director | $3,866,798 | -$577,961 | -13% | 08 Dec 2025 |
| Kyle Moran | Chief Financial Officer | $1,809,559 | -$4,103,979 | -69% | 08 Dec 2025 |
| PAUL BOLNO | President and CEO, Director | $1,221,858 | -$3,812,380 | -76% | 22 Aug 2025 |
| Chandra Vargeese | Chief Technology Officer, Head of Platform Discovery Sciences | $899,464 | 04 Mar 2025 | ||
| Heidi Wagner | Director | $629,020 | -$189,000 | -23% | 08 Dec 2025 |
| MARK CORRIGAN | Director | $405,282 | -$217,297 | -35% | 08 Dec 2025 |
| Chris Francis | SVP, Corporate Development, Head of Emerging Areas | $352,000 | -$6,427,085 | -95% | 08 Dec 2025 |
| Aik Na Tan | Director | $323,850 | -$2,027,270 | -86% | 08 Dec 2025 |
| CHRISTIAN HENRY | Director | $228,854 | -$1,557,091 | -87% | 08 Dec 2025 |
| Adrian Rawcliffe | Director | $190,500 | -$739,421 | -80% | 08 Dec 2025 |
| Michael A. Panzara | Chief Medical Officer, Head of Therapeutics Discovery and Development | 25 Jul 2022 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|